 HAMILTON, Bermuda, June 08, 2021 GLOBE NEWSWIRE -- Kiniksa Pharmaceuticals, Ltd. Nasdaq: KNSA Kiniksa, a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST rilonacept in the treatment of recurrent pericarditis. 